<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102657">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02093260</url>
  </required_header>
  <id_info>
    <org_study_id>Influenza 0213</org_study_id>
    <nct_id>NCT02093260</nct_id>
  </id_info>
  <brief_title>Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)</brief_title>
  <official_title>Phase II b Study of Immunogenicity and Safety of Flubio Vaccine in Infants and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <authority>Indonesia: National Agency of Drug and Food Control</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Asses the Immunogenicity and Safety of Flubio (Influenza HA) Vaccine in Infants and
      Children (Bridging Study)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Too see percentage of subjects with HI titer &gt;= 1:40, 28 days after two doses in infants and
      children (6 months-8 years old) and one dose in children 9-11 years old for each strain.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>To asses the immunogenicity of Flubio vaccine 28 days after 2 doses immunization in infants and children (6 months-8 years of age) and 1 dose immunization in children (9-11 years of age)</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with anti HI titer &gt;=1:40</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the seroconversion after 2 doses of Flubio vaccine in infants and children (6 months-8 years old)</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage subjects with increasing antibody titer &gt;=4 times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe seroconversion after 1 dose of Flubio vaccine in children (9-11 years old)</measure>
    <time_frame>1 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with transition of seronegative to seropositive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To asses the safety of Flubio vaccine</measure>
    <time_frame>1-2 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Local and Systemic Reaction following immunization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">405</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccine
Flubio (Influenza HA) vaccine
2 doses for infants and children (6 months - 8 years old)
1 doses for children (9-11 years old)
The vaccine will be given intramuscularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccine</intervention_name>
    <description>Flubio (Influenza HA) Vaccine
The vaccine will be given intramuscularly.</description>
    <arm_group_label>Vaccine</arm_group_label>
    <other_name>Flubio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Parents have been informed properly regarding the study and signed the informed
             consent form

          -  Parents will commit themselves to comply with the instructions of the investigator
             and the schedule of the trial

        Exclusion Criteria:

          -  Subjects concomitantly enrolled or scheduled to be enrolled in another trial

          -  Evolving mild, moderate, or severe illness, especially infectious diseases or fever
             (axillary temperature &gt;=37oC)

          -  Known history of allergy to egg and/or chicken protein or any other component of the
             vaccines

          -  Known history of uncontrolled coagulopathy or blood disorders contraindicating
             intramuscular injection

          -  Subject who has received a treatment likely to alter the immune response in the
             previous 4 weeks (intravenous immunoglobulins, blood-derived products or long term
             corticotherapy (&gt;2 weeks)).

          -  Any abnormality or chronic disease justified by investigator that might interfere
             assessment of the trial objectives.

          -  Subjects has been immunized with influenza vaccine within 1 year

          -  Subjects receives any vaccination within 1 months before and after immunization of
             Flubio.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernie Endyarni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Child Health School of Medicine, University of Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernie Endyarni, MD</last_name>
    <phone>+628158024517</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Jatinegara Primary Health Center</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernie Endyarni, MD</last_name>
      <phone>+628158024517</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary School of SDN 01 Kampung Melayu</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernie Endyarni, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>March 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flubio Vaccine (Influenza HA)</keyword>
  <keyword>Infants</keyword>
  <keyword>Children</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
